Genocea Biosciences Stock Working Capital
| GNCADelisted Stock | USD 0.0002 0.0001 100.00% |
Genocea Biosciences fundamentals help investors to digest information that contributes to Genocea Biosciences' financial success or failures. It also enables traders to predict the movement of Genocea Stock. The fundamental analysis module provides a way to measure Genocea Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genocea Biosciences stock.
Genocea |
Genocea Biosciences Company Working Capital Analysis
Genocea Biosciences' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Genocea Biosciences Working Capital | 69.32 M |
Most of Genocea Biosciences' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genocea Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionAccording to the company's disclosures, Genocea Biosciences has a Working Capital of 69.32 M. This is 83.71% lower than that of the Biotechnology sector and 87.13% lower than that of the Health Care industry. The working capital for all United States stocks is 95.31% higher than that of the company.
Genocea Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genocea Biosciences' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Genocea Biosciences could also be used in its relative valuation, which is a method of valuing Genocea Biosciences by comparing valuation metrics of similar companies.Genocea Biosciences is currently under evaluation in working capital category among its peers.
Genocea Fundamentals
| Return On Equity | -5.26 | |||
| Return On Asset | -0.58 | |||
| Operating Margin | (29.59) % | |||
| Current Valuation | (4.53 M) | |||
| Shares Outstanding | 58.78 M | |||
| Shares Owned By Insiders | 6.22 % | |||
| Shares Owned By Institutions | 1.25 % | |||
| Number Of Shares Shorted | 1.64 M | |||
| Price To Earning | (0.59) X | |||
| Price To Book | 0.01 X | |||
| Price To Sales | 0.12 X | |||
| Revenue | 1.64 M | |||
| Gross Profit | 1.64 M | |||
| EBITDA | (34.32 M) | |||
| Net Income | (33.2 M) | |||
| Cash And Equivalents | 20.14 M | |||
| Cash Per Share | 0.34 X | |||
| Total Debt | 8.79 M | |||
| Debt To Equity | 1.25 % | |||
| Current Ratio | 1.35 X | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (45.37 M) | |||
| Short Ratio | 0.74 X | |||
| Earnings Per Share | (0.53) X | |||
| Target Price | 3.08 | |||
| Number Of Employees | 74 | |||
| Beta | 1.6 | |||
| Market Capitalization | 5.88 K | |||
| Total Asset | 55.97 M | |||
| Retained Earnings | (339.66 M) | |||
| Working Capital | 69.32 M | |||
| Current Asset | 76.41 M | |||
| Current Liabilities | 7.09 M | |||
| Z Score | -7.2 | |||
| Net Asset | 55.97 M |
About Genocea Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genocea Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genocea Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genocea Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Genocea Stock
If you are still planning to invest in Genocea Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genocea Biosciences' history and understand the potential risks before investing.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |